DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on November 20, 2008; DOI: 10.1124/dmd.108.023648


0090-9556/09/3702-386-390$20.00
DMD 37:386-390, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.023648v1
37/2/386    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zamek-Gliszczynski, M. J.
Right arrow Articles by Brouwer, K. L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zamek-Gliszczynski, M. J.
Right arrow Articles by Brouwer, K. L. R.

Relationship between Drug/Metabolite Exposure and Impairment of Excretory Transport Function

Maciej J. Zamek-Gliszczynski, J. Cory Kalvass, Gary M. Pollack, and Kim L. R. Brouwer

Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana (M.J.Z.-G., J.C.K.); and School of Pharmacy, the University of North Carolina, Chapel Hill, North Carolina (G.M.P., K.L.R.B.)

The quantitative impact of excretory transport modulation on the systemic exposure to xenobiotics and derived metabolites is poorly understood. This article presents fundamental relationships between exposure and loss of a specific excretory process that contributes to overall clearance. The mathematical relationships presented herein were explored on the basis of hepatic excretory data for polar metabolites formed in the livers of various transporter-deficient rodents. Experimental data and theoretical relationships indicated that the fold change in exposure is governed by the relationship, 1/(1 – fe), where fe is the fraction excreted by a particular transport protein. Loss of function of a transport pathway associated with fe < 0.5 will have minor consequences (<2-fold) on exposure, but exposure will increase exponentially in response to loss of function of transport pathways with fe > 0.5. These mathematical relationships may be extended to other organs, such as the intestine and kidney, as well as to systemic drug exposure. Finally, the relationship between exposure and fe is not only applicable to complete loss of function of a transport pathway but also can be extended to partial inhibition scenarios by modifying the equation with the ratio of the inhibitor concentration and inhibition constant.


Address correspondence to: Dr. Maciej Zamek-Gliszczynski, Lilly Corporate Center, Indianapolis, IN 46285. E-mail: m_zamek-gliszczynski{at}lilly.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.